Sign in
Taking people in United StatesPhase 2

Tafasitamab with rituximab for newly diagnosed follicular lymphoma

Tests tafasitamab plus rituximab in adults newly diagnosed with follicular lymphoma.

Key facts

Who runs it
University of Washington
Where
Seattle, United StatesSee the site
Trial code
Registry title
Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma
Status
Recruiting
Phase
Phase 2
People taking part
30 people, planned
Started
9 Oct 2026
Expected to end
29 Oct 2032
Type of study
Interventional
Treatments tested
  • Rituximab
  • Tafasitamab
  • Biospecimen Collection
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Computed Tomography
  • Positron Emission Tomography
  • Survey Administration
Record updated
15 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with newly diagnosed follicular lymphoma (grade 1, 2 or 3A) who need to start treatment. They would get tafasitamab and rituximab.

Age
18 years or older
Sex
All sexes can join
Disease stage
Newly diagnosed follicular lymphoma, grade 1, 2 or 3A (or classic). Needs treatment, for example 3 or more lymph node sites of 3 cm (1.2 in) or more, a mass of 7 cm (2.8 in) or more, B symptoms, or low blood counts. Measurable disease is needed.
Earlier treatment
No monoclonal antibody within 4 weeks before the first dose. No treatment for lymphoma and no investigational therapy within 28 days before cycle 1. No live vaccine within 28 days.

Main reasons for not taking part

  • Grade 3B or transformed follicular lymphoma
  • Lymphoma in the central nervous system
  • Active, uncontrolled infection, or active hepatitis B or C
  • HIV infection, unless the viral load is undetectable and CD4 count is at least 400
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Age ≥ 18 years old
  • Patients must have histologic confirmation of follicular lymphoma (FL) (grade 1, 2, and 3A or classic follicular lymphoma)
  • Meeting any one of the following criteria for therapy initiation:; Involvement of ≥ 3 nodal sites, each with diameter of ≥ 3 cm; Any nodal or extranodal tumor mass with a diameter of ≥ 7 cm; B symptoms (fever ≥ 38 degrees Celsius of unclear etiology, night sweats, weight loss > 10% within the prior 6 months) attributed to FL; Risk of local compressive symptoms that may result in organ compromise; Splenomegaly with the inferior margin below the umbilical line or splenic lesion without splenomegaly; Significant cytopenia (absolute neutrophil count < 1500/mm3, platelets < 100,000/uL, hemoglobin < 10 g/dL); Leukemia (> 5,0000/uL circulating lymphocytes); Pleural effusion or ascites attributed to lymphoma
  • Have measurable nodal disease, including at least 1 disease site measuring at least 1.5 cm in longest dimension on CT or fludeoxyglucose (FDG)-PET, or a FDG-avid extranodal measurable site measuring at least 1.0 cm in longest dimension. Measurable disease also includes spleen size more than 13 cm in vertical length
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Absolute neutrophil count ≥ 1500/mm\^3 (unless due to lymphoma involvement of the bone marrow or spleen)
  • Platelets ≥ 75,000/mm\^3 (unless due to bone marrow involvement by lymphoma)
  • Hemoglobin ≥ 8 g/dL (unless due to bone marrow involvement by lymphoma)
  • Total bilirubin ≤ 2.0 mg/dL, except for patients with documented lymphoma involvement of liver or with a known history of Gilbert's disease
  • Alkaline phosphatase/aspartate aminotransferase (AST)/(serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) ≤ 3 × institutional upper limit of normal, except for patients with documented liver involvement
  • Creatinine clearance ≥ 30 ml/min
  • Fertile male and women of child bearing potential (WOCBP) patients must be willing to use highly effective contraceptive methods from study recruitment to at least 6 months after the last dose of study treatment
  • Ability to understand and willingness to sign a written informed consent document

Who cannot take part

  • Patients receiving any other investigational agents
  • Prior use of any monoclonal antibody within 4 weeks before the first administration
  • Serologic status reflecting active hepatitis B or C infection. Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody are eligible if the corresponding polymerase chain reaction (PCR) test is negative prior to enrollment. Hepatitis B core antibody (+) patients without evidence of HBsAg or Hep B PCR (+) are eligible with appropriate Hepatitis B reactivation prophylaxis as per institutional guidelines
  • Major surgery (excluding lymph node biopsy) within 28 days prior to signing the informed consent form (ICF) unless the participant is recovered at the time of signing the ICF
  • Any systemic anti-lymphoma and/or investigational therapy within 28 days prior to the start of cycle 1
  • Administration of a live vaccine within 28 days prior to the start of study treatment (cycle 1 day 1)
  • History of a second primary malignancy that could affect compliance with the protocol or interpretation of results except with permission of the principal investigator. Malignancies treated curatively or at low-risk of progressing at the judgment of the primary investigator (PI) may be included
  • Known active and uncontrolled bacterial, viral, fungal, mycobacterial, or other infection at study enrollment
  • Uncontrolled intercurrent illness such as: history of myocardial infarction (MI) in the last 6 months, congestive heart failure New York Heart Association (NYHA) Class III-IV, uncontrolled or symptomatic arrhythmia, stroke in last 6 months, liver cirrhosis, and autoimmune disorder requiring immunosuppression or long-term corticosteroids (> 10 mg daily prednisone equivalent)
  • History of hypersensitivity to compounds of similar biological or chemical composition to tafasitamab, immunomodulatory drugs, rituximab, other monocolonal antibodies (mAbs), and/or the excipients contained in the study drug formulations
  • History of human immunodeficiency virus (HIV) infection uncles the viral load is undetectable and CD4 count is at least 400
  • History or evidence of rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
  • FL grade 3B or transformed FL
  • Patients with known central nervous system involvement of lymphoma
  • Breastfeeding or pregnant women

Where in United States

  • Fred Hutch/University of Washington Cancer ConsortiumSeattle, United StatesContact: Mengyang Di, MD, PhDTaking people

About the trial

What the trial wants to find out

This phase II trial tests how well tafasitamab and rituximab works for the treatment of newly diagnosed follicular lymphoma. Tafasitamab is a monoclonal antibody. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving tadasitamab and rituximab may work well to treat patients with newly diagnosed follicular lymphoma.

The group in the trial

  • Treatment (Tafasitamab and rituximab)Treatment being tested

    CYCLES 1-3: Patients receive rituximab IV on day 1 and tafasitamab IV on days 1, 8, 15 and 22 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. CYCLES 4-6; Patients receive rituximab IV on day 1 and tafasitamab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo disease assessment. Patients with complete response undergo active surveillance. Patients with less than complete response go on to receive cycles 7-12. CYCLES 7-12: Patients receive tafasitamab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo PET scan, CT scan, bone marrow biopsy and aspiration and blood sample collection throughout the study.

    Treatment: Rituximab, Tafasitamab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, and Survey Administration

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
TREND-FL: Tafasitamab and Rituximab to Enhance Outcomes in Patients With Newly Diagnosed Follicular Lymphoma
Plain-language title
Tafasitamab with rituximab for newly diagnosed follicular lymphomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
15 October 2026